Comparison Between Effect of Vitamin D Versus Dexmedetomidine in Patients with Head Trauma Using Interleukin 6

Minia University

Status: Completed

Conditions: Traumatic Brain Injury

Treatments: Drug: Vitamin D3; Drug: Dexmedetomidine

Study type: Observational

Funder types: Other

Identifiers

NCT06565338

403

Details and patient eligibility

About

in this study the investigators compare between the neuroprotective effect of vitamin d versus dexmedetomidine in patients with traumatic brain injury using interleukin 6 as inflammatory biomarker

Full description

patients with moderate head trauma (GCS 8-12) within first 24 hours were randomly divided into 2 groups, first group received 100,000 IU of vitamin D was given IM & the other group received dexmedetomidine 0.4 mic/kg as loading dose then 0.25 mic/kg/hr as maintainence dose for 5 days detecting APATCHE at admission and following up of vital signs (HR & NIBP) & investigations (CBC & RFT& ABG & ESR& CRP & IL-6) & GCS and GOS for 5 days.

Enrollment: 60 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Both Gender.
• Age (18-50)
• GCS (8-12)
• Pt with traumatic brain insult who not indicated surgical intervention

Exclusion criteria

• Prior severe disability.
• Isolated brain system lesions.
• History of underlying neurologic, metabolic or psychiatric disorders.
• Alcohol or drug abuse.
• Pregnancy.
• Patients with intracranial hemorrhage who indicated surgical evacuation.
• Multisystem life-threatening trauma.
• GCS > 12 & <8.
• Vitamin d deficiency.

Trial design

60 participants in 2 patient groups

group A

Description:

dexmedetomidine 0.4 mic/kg loading dose then 0.25 mic/kg/hr for 5 days

Treatment:

Drug: Dexmedetomidine

group B

Description:

vitamin D 100.000 IU given IM once

Treatment:

Drug: Vitamin D3